Valneva submits chikungunya vaccine marketing application to ema and announces chmp accelerated assessment

Saint-herblain (france), october 25, 2023 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announces the submission of a marketing application with the european medicines agency (ema) for approval of the company's single-shot chikungunya vaccine candidate, vla1553. valneva was also granted accelerated assessment1 for the application by ema's committee for medicinal products for human use (chmp) based on the vaccine candidate's “major interest for public health and therapeutic innovation”.
VALN Ratings Summary
VALN Quant Ranking